Long-Term Cost Effectiveness of Early and Sustained Dual Oral Antiplatelet Therapy With Clopidogrel Given for Up to One Year After Percutaneous Coronary Intervention
Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial
Sean C. Beinart, MD, MSc*,
Paul Kolm, PhD*,
Emir Veledar, PhD*,
Zefeng Zhang, MD, PhD*,
Elizabeth M. Mahoney, ScD ,
Olivier Bouin, MD ,
Sylvie Gabriel, MD,
Joseph Jackson, PhD ,
Roland Chen, MD,
Jaime Caro, MD||,
Steven Steinhubl, MD¶,
Eric Topol, MD# and
William S. Weintraub, MD*,*
* Emory University, Atlanta, Georgia
New England Research Institutes, Watertown, Massachusetts
Sanofi-Aventis, Paris, France
Bristol-Myers Squibb, Princeton, New Jersey
|| Caro Research Institute, Concord, Massachusetts
¶ University of Kentucky, Lexington, Kentucky
# Cleveland Clinic, Cleveland, Ohio
View larger version (47K):
[in a new window]
|
Figure 1 Scatterplot of the joint distribution of bootstrap estimates of cost and effectiveness differences based on Blended costs for Framingham (left) and Saskatchewan (right) life expectancy estimates. The line extending through the origin (0.0) is a hypothetical cost-effectiveness threshold of $50,000 per life-year gained.
|
|
View larger version (29K):
[in a new window]
|
Figure 2 Cost-effectiveness acceptability curves based on Medicare/MEDSTAT costs for Framingham and Saskatchewan life expectancy estimates. CE = cost effectiveness.
|
|
|
